Patents by Inventor Huilei Xu

Huilei Xu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • STEROL REGULATORY ELEMENT BINDING PROTEIN (SREBP) CHAPERONE (SCAP) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
    Publication number: 20230093948
    Abstract: The invention relates to double stranded ribonucleic acid (dsRNAi) agents and compositions targeting the SCAP gene, as well as methods of inhibiting expression of a SCAP gene and methods of treating subjects having a SCAP-associated disorder, such as nonalcoholic fatty liver disease (NAFLD) or nonalcoholic steatohepatitis (NASH), using such dsRNAi agents and compositions.
    Type: Application
    Filed: July 8, 2022
    Publication date: March 30, 2023
    Inventors: Kevin Fitzgerald, Huilei Xu, Gregory Hinkle
  • Sterol regulatory element binding protein (SREBP) chaperone (SCAP) iRNA compositions and methods of use thereof
    Patent number: 11434487
    Abstract: The invention relates to double stranded ribonucleic acid (dsRNAi) agents and compositions targeting the SCAP gene, as well as methods of inhibiting expression of a SCAP gene and methods of treating subjects having a SCAP-associated disorder, such as nonalcoholic fatty liver disease (NAFLD) or nonalcoholic steatohepatitis (NASH), using such dsRNAi agents and compositions.
    Type: Grant
    Filed: July 27, 2020
    Date of Patent: September 6, 2022
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Kevin Fitzgerald, Huilei Xu, Gregory Hinkle
  • INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN, ACID LABILE SUBUNIT (IGFALS) AND INSULIN-LIKE GROWTH FACTOR 1 (IGF-1) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
    Publication number: 20220042012
    Abstract: The present invention relates to RNAi agents, e.g., double stranded RNAi agents, targeting the insulin-like growth factor binding protein, acid labile subunit (IGFALS) gene or the insulin-like growth factor 1 (IGF-1) gene, methods of using such double stranded RNAi agents to inhibit expression of an IGFALS gene or an IGF-1 gene, and methods of treating subjects having an IGF system-associated disorder.
    Type: Application
    Filed: June 17, 2021
    Publication date: February 10, 2022
    Inventors: James Butler, Kevin Fitzgerald, Gregory Hinkle, Brian Bettencourt, Huilei Xu
  • COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE LECT2 GENE
    Publication number: 20210348162
    Abstract: The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the LECT2 gene, and methods of using such dsRNA compositions to alter (e.g., inhibit) expression of LECT2.
    Type: Application
    Filed: August 15, 2019
    Publication date: November 11, 2021
    Inventors: Gregory Hinkle, Huilei Xu
  • Insulin-like growth factor binding protein, acid labile subunit (IGFALS) and insulin-like growth factor 1 (IGF-1) iRNA compositions and methods of use thereof
    Patent number: 11066670
    Abstract: The present invention relates to RNAi agents, e.g., double stranded RNAi agents, targeting the insulin-like growth factor binding protein, acid labile subunit (IGFALS) gene or the insulin-like growth factor 1 (IGF-1) gene, methods of using such double stranded RNAi agents to inhibit expression of an IGFALS gene or an IGF-1 gene, and methods of treating subjects having an IGF system-associated disorder.
    Type: Grant
    Filed: October 15, 2019
    Date of Patent: July 20, 2021
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: James Butler, Kevin Fitzgerald, Gregory Hinkle, Brian Bettencourt, Huilei Xu
  • STEROL REGULATORY ELEMENT BINDING PROTEIN (SREBP) CHAPERONE (SCAP) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
    Publication number: 20210002638
    Abstract: The invention relates to double stranded ribonucleic acid (dsRNAi) agents and compositions targeting the SCAP gene, as well as methods of inhibiting expression of a SCAP gene and methods of treating subjects having a SCAP-associated disorder, such as nonalcoholic fatty liver disease (NAFLD) or nonalcoholic steatohepatitis (NASH), using such dsRNAi agents and compositions.
    Type: Application
    Filed: July 27, 2020
    Publication date: January 7, 2021
    Inventors: Kevin Fitzgerald, Huilei Xu, Gregory Hinkle
  • HEPATITIS D VIRUS (HDV) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
    Publication number: 20200291405
    Abstract: The present invention relates to RNAi agents, e.g., double-stranded RNAi agents, targeting the hepatitis D virus (HDV) genome, and methods of using such RNAi agents to inhibit expression of one or more HBV genes and methods of treating subjects having an HDV infection and/or HDV-associated disorder.
    Type: Application
    Filed: February 26, 2020
    Publication date: September 17, 2020
    Inventors: Gregory Hinkle, Laura Sepp-Lorenzino, Vasant R. Jadhav, Martin A. Maier, Muthiah Manoharan, Stuart Milstein, Svetlana Shulga Morskaya, Kallanthottathil G. Rajeev, Huilei Xu
  • Sterol regulatory element binding protein (SREBP) chaperone (SCAP) iRNA compositions and methods of use thereof
    Patent number: 10767177
    Abstract: The invention relates to double stranded ribonucleic acid (dsRNAi) agents and compositions targeting the SCAP gene, as well as methods of inhibiting expression of a SCAP gene and methods of treating subjects having a SCAP-associated disorder, such as nonalcoholic fatty liver disease (NAFLD) or nonalcoholic steatohepatitis (NASH), using such dsRNAi agents and compositions.
    Type: Grant
    Filed: June 7, 2018
    Date of Patent: September 8, 2020
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Kevin Fitzgerald, Huilei Xu, Gregory Hinkle
  • INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN, ACID LABILE SUBUNIT (IGFALS) AND INSULIN-LIKE GROWTH FACTOR 1 (IGF-1) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
    Publication number: 20200277599
    Abstract: The present invention relates to RNAi agents, e.g., double stranded RNAi agents, targeting the insulin-like growth factor binding protein, acid labile subunit (IGFALS) gene or the insulin-like growth factor 1 (IGF-1) gene, methods of using such double stranded RNAi agents to inhibit expression of an IGFALS gene or an IGF-1 gene, and methods of treating subjects having an IGF system-associated disorder.
    Type: Application
    Filed: October 15, 2019
    Publication date: September 3, 2020
    Inventors: James Butler, Kevin Fitzgerald, Gregory Hinkle, Brian Bettencourt, Huilei Xu
  • Hepatitis D virus (HDV) iRNA compositions and methods of use thereof
    Patent number: 10640770
    Abstract: The present invention relates to RNAi agents, e.g., double-stranded RNAi agents, targeting the hepatitis D virus (HDV) genome, and methods of using such RNAi agents to inhibit expression of one or more HBV genes and methods of treating subjects having an HDV infection and/or HDV-associated disorder.
    Type: Grant
    Filed: May 10, 2017
    Date of Patent: May 5, 2020
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Gregory Hinkle, Laura Sepp-Lorenzino, Vasant Jadhav, Martin Maier, Muthiah Manoharan, Stuart Milstein, Svetlana Shulga Morskaya, Kallanthottathil G. Rajeev, Huilei Xu
  • Insulin-like growth factor binding protein, acid labile subunit (IGFALS) compositions and methods of use thereof
    Patent number: 10494632
    Abstract: The present invention relates to RNAi agents, e.g., double stranded RNAi agents, targeting the insulin-like growth factor binding protein, acid labile subunit (IGFALS) gene or the insulin-like growth factor 1 (IGF-1) gene, methods of using such double stranded RNAi agents to inhibit expression of an IGFALS gene or an IGF-1 gene, and methods of treating subjects having an IGF system-associated disorder.
    Type: Grant
    Filed: July 8, 2016
    Date of Patent: December 3, 2019
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: James Butler, Kevin Fitzgerald, Gregory Hinkle, Brian Bettencourt, Huilei Xu
  • STEROL REGULATORY ELEMENT BINDING PROTEIN (SREBP) CHAPERONE (SCAP) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
    Publication number: 20180273955
    Abstract: The invention relates to double stranded ribonucleic acid (dsRNAi) agents and compositions targeting the SCAP gene, as well as methods of inhibiting expression of a SCAP gene and methods of treating subjects having a SCAP-associated disorder, such as nonalcoholic fatty liver disease (NAFLD) or nonalcoholic steatohepatitis (NASH), using such dsRNAi agents and compositions.
    Type: Application
    Filed: June 7, 2018
    Publication date: September 27, 2018
    Inventors: Kevin Fitzgerald, Huilei Xu, Gregory Hinkle
  • INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN, ACID LABILE SUBUNIT (IGFALS) AND INSULIN-LIKE GROWTH FACTOR 1 (IGF-1) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
    Publication number: 20180201929
    Abstract: The present invention relates to RNAi agents, e.g., double stranded RNAi agents, targeting the insulin-like growth factor binding protein, acid labile subunit (IGFALS) gene or the insulin-like growth factor 1 (IGF-1) gene, methods of using such double stranded RNAi agents to inhibit expression of an IGFALS gene or an IGF-1 gene, and methods of treating subjects having an IGF system-associated disorder.
    Type: Application
    Filed: July 8, 2016
    Publication date: July 19, 2018
    Inventors: James Butler, Kevin Fitzgerald, Gregory Hinkle, Brian Bettencourt, Huilei Xu
  • HEPATITIS D VIRUS (HDV) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
    Publication number: 20170349901
    Abstract: The present invention relates to RNAi agents, e.g., double-stranded RNAi agents, targeting the hepatitis D virus (HDV) genome, and methods of using such RNAi agents to inhibit expression of one or more HBV genes and methods of treating subjects having an HDV infection and/or HDV-associated disorder.
    Type: Application
    Filed: May 10, 2017
    Publication date: December 7, 2017
    Inventors: Gregory Hinkle, Laura Sepp-Lorenzino, Vasant Jadhav, Martin Maier, Muthiah Manoharan, Stuart Milstein, Svetlana Shulga Morskaya, Kallanthottathil G. Rajeev, Huilei Xu